Fasting Insulin

Almost every checkup includes a blood sugar test, and for most people it comes back normal for years. That normal result is reassuring, and it is also one of the most misleading numbers in routine medicine.

Blood sugar is not the first thing to go wrong in metabolic disease. It is one of the last. Long before glucose drifts upward, the body fights to hold it in place, and the cost of that fight is rising insulin. A person can spend a decade or more with flawless blood sugar while their pancreas works harder and harder behind the scenes to keep it that way. By the time glucose finally climbs, the underlying problem has been building, untreated, for years.

Fasting insulin is the number that exposes this hidden stretch. Instead of measuring the result, blood sugar, it measures the effort, how much insulin your body is secreting to keep that sugar normal. When that effort is high, you are looking at insulin resistance in its earliest and most reversible form, often a decade before any standard test would flag it ^[1].

It is one of the most useful markers almost nobody is given. Standard care tracks the lagging signal and misses the leading one entirely.

Insulin is a hormone made by the beta cells of the pancreas, released in response to rising blood glucose. Its core job is to move glucose out of the bloodstream and into muscle, liver, and fat, and to tell the liver to stop making more. When the system works, a small amount of insulin keeps blood sugar in a tight band.

Insulin resistance is the state in which muscle, liver, and fat cells respond less to a given amount of insulin. The pancreas compensates by secreting more, and this compensated phase, normal glucose held up by high insulin, can persist for years ^[2]. Fasting insulin rises during this phase while glucose stays flat, which is precisely why it is the earlier marker. The pairing of fasting insulin with fasting glucose in a simple calculation called HOMA-IR sharpens the estimate of how resistant a person has become.

The high insulin itself is not a harmless bystander. Elevated insulin drives the liver to produce more triglycerides, promotes fat storage, encourages sodium retention that nudges blood pressure up, and shifts the whole metabolic environment toward the pattern seen in metabolic syndrome ^[2]. The chief drivers on the way in are familiar: a steady surplus of refined carbohydrate and sugar, accumulating visceral fat, inactivity, poor sleep, and chronic stress.

The clearest demonstration of how much this marker reveals comes from the work of Joseph Kraft, who measured insulin responses in thousands of people with ostensibly normal glucose tolerance and found that a large share already had abnormal, exaggerated insulin patterns. He described it as diabetes being missed in plain sight, hidden behind a glucose test that looked fine ^[1]. Fasting insulin captures a simpler version of the same truth: the dysfunction is measurable long before glucose moves.

It also predicts what comes next. Elevated fasting insulin independently forecasts the later development of type 2 diabetes, identifying risk years in advance of the diagnosis ^[3]. And the same insulin-resistant state sits underneath much of cardiovascular disease, hypertension, and the high-triglyceride, low-HDL lipid pattern that travels with it, which is why insulin resistance is best understood as an upstream condition with many downstream faces ^[2]. That lipid signature is consistent enough that insulin resistance can be estimated from the lipoprotein profile alone, even when fasting glucose looks normal ^[4].

Two cautions matter for interpretation. First, insulin assays are not well standardized between laboratories. Different platforms use different antibodies, which cross-react to varying degrees with insulin's precursor, proinsulin, and they are calibrated against different reference standards, so the same blood can read meaningfully differently from one lab to the next. That makes tracking your own trend at a single lab far more reliable than fixating on any one value. Second, the "normal" range is misleadingly lenient. A fasting insulin ordered through our Ulta store runs on Quest, whose report labels anything up to 18.4 µIU/mL "optimal" and only flags a value above that as high. That cutoff comes from a general population already full of insulin-resistant people, so it sits far above a genuinely healthy level. A result resting inside the "optimal" band can still represent meaningful resistance. A longevity-minded target is much lower, generally under 5 to 8 µIU/mL.